In the following video, Motley Fool health care bureau chief Brenton Flynn discusses the lack of a pathway in the United States for approving drugs that are being called "biosimilars," in that they are similar to biological large-molecule drugs like how generic pharmaceuticals currently are similar to small-molecule drugs. Brenton discusses why this has remained such an untapped market in the U.S. and what the difficulties are in producing these far more complex drugs in the form of a marketable generic. He also tells us which companies stand to benefit from legislation putting a pathway to approval for these drugs into place in the U.S., and why companies like AbbVie (NYSE:ABBV) would benefit from such legislation being delayed.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
5 Things Amgen's CEO Just Said That Investors Need to Know
Bob Bradway focused on acquisitions, growth, and more at the J.P. Morgan Healthcare Conference.
2 Top Dividend Stocks to Buy in 2018
If you're looking for rock solid dividends, AbbVie and Amgen should be on your radar this year.
3 Biotech Stocks to Buy in January
Amgen, Celldex Therapeutics, and Novavax could all outperform in 2018.